$NWBO $MRNA $MRK $BNTX $RHHBY #ESMO26 #DCVax #CancerVaccines #RareCancers #GBM #DendriticCells @NorthwestBio @parkerici @FDA @FDA_KyleD @DrOzCMS @SecKennedy @MHRAgovuk @ReaganUdall 𝗧𝗵𝗲 𝗡𝗮𝗺𝗲 𝗖𝗮𝗺𝗲 𝗙𝗶𝗿𝘀𝘁 Braelyn Hollensbe was 16 when her family was told she had a brain cancer almost nobody gets: diffuse hemispheric glioma, H3 G34-mutant. The World Health Organization gave that tumor a name of its own in 2021. No proven treatment has ever been built for it. 𝗧𝗵𝗲 𝗻𝗮𝗺𝗲 𝗰𝗮𝗺𝗲 𝗳𝗶𝗿𝘀𝘁, 𝗮𝗻𝗱 𝗶𝘁 𝗰𝗮𝗺𝗲 𝗮𝗹𝗼𝗻𝗲. Three years of surgery, infection and radiation. Then, in March, a UCLA surgeon removed most of the tumor and preserved the tissue. The names had never given her family a plan. The tissue did. Her tumor went to England before she did. A laboratory there broke it down and used it to teach dendritic cells grown from her own blood. In July, at King's College Hospital in London, she received a vaccine that existed for exactly one person. In August came the checkpoint drug: vaccine first, then the brakes released. On September 15 her mother posted the sentence she had waited almost three years to write: 𝗡𝗼 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗼𝗳 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. Braelyn is 19 and in college. She still flies to London for boosters, because no route yet exists to give her her own cells at home. One case proves nothing on its own. The record behind her vaccine is not one case. Dendritic cells are the immune system's teachers. They take up tumor material, cut it into fragments, select what the patient's own T cells can see and deliver the order to attack. A tumor's sequence can list its antigens. It cannot teach them. Antigen information and a prepared instructor are different contributions, and in a patient whose cancer and treatment have depleted the immune system, the missing piece is the instructor. DCVax-L brings the removed tumor to those cells and returns them loaded. DCVax-Direct brings prepared cells into a tumor a needle can reach, where they learn from the tumor as it is that day. Both are made for a population of one. This platform has practiced rare-disease medicine, one patient at a time, since its first trial. Glioblastoma: no new drug has extended survival in newly diagnosed disease since 2005. Three large checkpoint trials, 1,645 patients, no survival benefit. On that ground, the Phase 3 program's published analyses reported 13% of vaccinated newly diagnosed patients alive at five years against 5.7% in the external comparison group. This year, matching vaccinated patients one by one to patient-level records from other trials strengthened the median-survival finding. Across 2,151 doses: five serious events judged possibly related. No autoimmune reactions. And a UCLA series reported this fall found that giving the vaccine before a checkpoint inhibitor, not after, more than doubled median survival in a small cohort. 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻, 𝘁𝗵𝗲𝗻 𝗮𝗺𝗽𝗹𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻. One of the earliest trial participants, diagnosed in 2003 as he was about to become a father, was described this year as a 23-year survivor. That is what durable survival means. 𝗬𝗲𝗮𝗿𝘀 𝘄𝗶𝘁𝗵 𝗽𝗲𝗼𝗽𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲𝗺. On 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟴, FDA holds its public meeting on the Rare Disease Framework. Written comments close 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟭𝟭. The meeting approves nothing. It helps shape what the agency will ask for. That is exactly why it matters. The evidence exists: survival analyses that held under patient-level comparison, a measured safety record, product function tied to patient outcomes, manufacturing already built, and 2,151 doses of human experience. What must come next is a written answer to three questions. What evidence is still required? Who will produce it? When will it be judged? @FDA @FDA_KyleD: name the evidence, name the producer, name the date. A treatment made from one person's cells deserves a review built for it: safety, manufacturing, endpoints that measure a life, and a route to access, in one conversation. Braelyn's family answered the access question by crossing an ocean. The next family should not have to. Rarity is a fact about how often a label is applied. It must never become an excuse for how little a life is allowed to matter. 𝗢𝗻𝗲 𝗶𝗻 𝗮 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘀𝗼𝗺𝗲𝗼𝗻𝗲'𝘀 𝘄𝗵𝗼𝗹𝗲 𝘄𝗼𝗿𝗹𝗱. Read the full article: xitter.cf/andrewcaravello/articl…